Andrew Freistein 10/524,993

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptabf1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 5	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 6	MAY 11	KOREAPAT updates resume
NEWS 7	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 8	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 9	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 10	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS 11	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 12	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 13	JUl 11	CHEMSAFE reloaded and enhanced
NEWS 14	JUl 14	FSTA enhanced with Japanese patents
NEWS 15	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS 16	AUG 09	INSPEC enhanced with 1898-1968 archive

NEWS EXPRESS	JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:19:14 ON 16 AUG 2006

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:19:26 ON 16 AUG 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 AUG 2006 HIGHEST RN 901654-60-2
DICTIONARY FILE UPDATES: 15 AUG 2006 HIGHEST RN 901654-60-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10524993\a.str



chain nodes :
18 19 25 26 27 28
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 20 21 22 23 24

```
chain bonds :
1-7  4-19  12-13  16-18  19-20  21-28  23-27  24-25  25-26
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12  13-14  13-17
14-15  15-16  16-17  20-21  20-24  21-22  22-23  23-24
exact/norm bonds :
13-14  13-17  14-15  15-16  16-17  20-21  20-24  21-22  22-23  23-24
exact bonds :
1-7  4-19  12-13  16-18  19-20  21-28  23-27  24-25  25-26
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:CLASS  19:CLASS
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:CLASS  26:CLASS  27:CLASS  28:CLASS




L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 11:19:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       34 TO ITERATE

100.0% PROCESSED       34 ITERATIONS                                 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          331 TO     1029
PROJECTED ANSWERS:               2 TO      124

L2            2 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 11:19:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      673 TO ITERATE

100.0% PROCESSED      673 ITERATIONS                                34 ANSWERS
SEARCH TIME: 00.00.01

L3           34 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     166.94     167.15
```

```
FILE 'CAPLUS' ENTERED AT 11:20:05 ON 16 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 16 Aug 2006  VOL 145 ISS 8
FILE LAST UPDATED: 15 Aug 2006  (20060815/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4        2811 L3

=> s l4 and polymorph? or cyrstalline
        191744 POLYMORPH?
            21 CYRSTALLINE
L5          68 L4 AND POLYMORPH? OR CYRSTALLINE

=> s losartan
          4698 LOSARTAN
             1 LOSARTANS
L6        4698 LOSARTAN
                 (LOSARTAN OR LOSARTANS)

=> s polymorph or crystal?
          7423 POLYMORPH
          8513 POLYMORPHS
         12981 POLYMORPH
                 (POLYMORPH OR POLYMORPHS)
       1765010 CRYSTAL?
        345195 CRYST
          1801 CRYSTS
        346463 CRYST
                 (CRYST OR CRYSTS)
         89394 CRYSTD
         18928 CRYSTG
        232964 CRYSTN
          2373 CRYSTNS
        234266 CRYSTN
                 (CRYSTN OR CRYSTNS)
       2064318 CRYSTAL?
                 (CRYSTAL? OR CRYST OR CRYSTD OR CRYSTG OR CRYSTN)
L7     2067837 POLYMORPH OR CRYSTAL?

=> s l7 and l6
```

```
L8          57 L7 AND L6

=> s l8 and potassium
        597707 POTASSIUM
            16 POTASSIUMS
        597709 POTASSIUM
                  (POTASSIUM OR POTASSIUMS)
L9          27 L8 AND POTASSIUM

=> d scan

L9    27 ANSWERS   CAPLUS  COPYRIGHT 2006 ACS on STN
IC   ICM  A61K031-4178
     ICS  A61P009-12; C07D403-10
CC   63-6 (Pharmaceuticals)
     Section cross-reference(s): 28
TI   Purification methods in preparation of pharmaceutical salts of
     losartan
ST   pharmaceutical salt losartan property prepn
IT   Crystal structure
        (of losartan salts)
IT   Density
     Dissolution
     Flow
     Freeze drying
     Particle size distribution
     Polymorphism (crystal)
     Solubility
     Stability
     Surface area
        (purification methods in preparation of pharmaceutical salts of losartan
        )
IT   Alcohols, processes
     RL: PEP (Physical, engineering or chemical process); PYP (Physical
     process); PROC (Process)
        (purification methods in preparation of pharmaceutical salts of losartan
        )
IT   Alkali metal hydroxides
     Alkali metals, reactions
     Alkaline earth hydroxides
     Alkaline earth metals
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (purification methods in preparation of pharmaceutical salts of losartan
        )
IT   Drug delivery systems
        (tablets, coated; purification methods in preparation of pharmaceutical
salts of
        losartan)
IT   9004-34-6, Cellulose, biological studies
     RL: PEP (Physical, engineering or chemical process); PYP (Physical
     process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);
     USES (Uses)
        (microcryst.; purification methods in preparation of pharmaceutical salts of
        losartan)
IT   60-29-7, Diethyl ether, processes   67-56-1, Methanol, processes
     67-63-0, 2-Propanol, processes   141-78-6, EtOAc, processes   142-82-5,
     Heptane, processes
     RL: PEP (Physical, engineering or chemical process); PYP (Physical
     process); PROC (Process)
        (purification methods in preparation of pharmaceutical salts of losartan
```

)
IT 7631-86-9, Silica, biological studies 64044-51-5 74811-65-7, Croscarmellose sodium
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(purification methods in preparation of pharmaceutical salts of losartan
)
IT 114798-26-4DP, Losartan, salts 124750-99-8P, Losartan potassium 733047-57-9P 733047-58-0P 733047-59-1P
RL: PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(purification methods in preparation of pharmaceutical salts of losartan
)
IT 865-47-4 865-48-5 1305-62-0, Calcium hydroxide, reactions 2414-98-4, Magnesium ethoxide 79047-41-9 133051-88-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(purification methods in preparation of pharmaceutical salts of losartan
)
IT 114798-26-4P, Losartan 133909-99-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(purification methods in preparation of pharmaceutical salts of losartan
)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d ibib abs 1-27

L9 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:699729 CAPLUS
DOCUMENT NUMBER: 145:152705
TITLE: Stable noncrystalline formulations comprising losartan
INVENTOR(S): Palakodaty, Srinivas; Kordikowski, Andreas; Daintree, Linda Sharon; Duddu, Sarma; Kugler, Alan; Zhang, Jiang; Snyder, Herman; Lechuga, David; Palepu, Nagesh; Eldon, Michael A.
PATENT ASSIGNEE(S): Nektar Therapeutics, USA
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006076097	A2	20060720	WO 2005-US44278	20051206

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006160871 A1 20060720 US 2005-296108 20051206
PRIORITY APPLN. INFO.: US 2004-633988P P 20041207

AB One or more embodiments of the invention provide various novel formulations, and tablet dosage forms, comprising losartan that are noncryst., stable, and/or otherwise improvements over known losartan formulations. One or more embodiments of the invention further provide methods for preparing the formulation, methods for preparing the tablet dosage form, and to methods of administering the tablet dosage and/or formulation comprising losartan. The losartan -containing formulations may be administered to a user to treat hypertension, and related conditions. A spray drying process is used to produce particles comprising non-crystalline losartan and a stabilizing excipient. The stabilizing excipient comprises a copolymer, such as a vinyl pyrrolidone-vinyl acetate copolymer.

L9 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:430764 CAPLUS
DOCUMENT NUMBER: 145:46064
TITLE: Process for preparation of H-type crystalline form of losartan potassium
INVENTOR(S): Wang, Youhu; Zhou, Minghua; Hu, Gongyun; Wang, Danhua; Jin, Yongjun; Chai, Jian; Li, Wei
PATENT ASSIGNEE(S): Zhejiang Huahai Pharmaceutical Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 15 pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1763036	A	20060426	CN 2004-10067407	20041022

PRIORITY APPLN. INFO.: CN 2004-10067407 20041022

AB The title crystalline form of losartan potassium features in having characteristic absorption peak 2θ of 7.11, 7.32, 11.08, 14.24, 14.80, 18.55, 18.93, 21.38, 23.90, 28.72, 29.88, 30.97, 33.11 according to XRD pattern, and exhibiting maximum endothermic fusion peak at 273.37°C, maximum endothermic onset temperature of crystalline transition of 235.47°C under detection condition of 30-300°C, heating rate of 10°C/min, open, and nitrogen gas flow of 40 mL/min according to DSC thermogram. The title method comprises dissolving losartan potassium in alc. optionally containing water 1-15%, adding mixture of hydrocarbon/alc. with volume ratio of 10:1-20:1, cooling to 0-30°C, stirring for 0.5-1 h, standing for 1-3 h, separating, and drying at 20-120°C to obtain the final product.

L9 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:343149 CAPLUS
DOCUMENT NUMBER: 144:370099
TITLE: Alkylation and reduction process for preparation of 2-butyl-4-chloro-1-[[2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl]-1H-imidazole-5-methanol which is a losartan intermediate
INVENTOR(S): Chava, Satyanaryana; Vasireddy, Umamaheswar Rao; Vellanki, Siva Ram Prasad; Balusu, Rajababu

PATENT ASSIGNEE(S): Matrix Laboratories Ltd., India
SOURCE: PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006038223	A1	20060413	WO 2005-IN308	20050913

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: IN 2004-CH1032 A 20041006
OTHER SOURCE(S): CASREACT 144:370099
AB 2-Butyl-4-chloro-1-[[2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl]-1H-imidazole-5-methanol (I), an intermediate in the synthesis of losartan and its pharmaceutically acceptable salts, is prepared in high yield and selectivity by: (A) the alkylation of 2-butyl-4-chloroimidazole-5-carboxaldehyde with 5-(4'-bromomethyl-1,1'-biphenyl-2-yl)-1-(triphenylmethyl)-1H-tetrazole in water and a haloalkane (e.g., 1-chlorobutane) in the presence of a base (e.g., NaOH) and a phase-transfer catalyst (e.g., tetrabutylammonium bromide); (B) maintaining the reaction mass at 10-65° for 18-48 h; (C) letting the reaction mixture settle and separating the aqueous and organic layers; (D) reacting the organic layer with sodium borohydride and a lower alc. (e.g., methanol); (E) adding water to the reaction mass and separating the layers; (F) washing the organic layer with water; (G) concentrating the organic layer; (H) isolating the I and drying it at 45-75°; and (I) conducting an optional crystallization of I if necessary.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1004564 CAPLUS
DOCUMENT NUMBER: 143:292576
TITLE: Stabilization of a polymorphic form of losartan potassium
INVENTOR(S): Svete, Peter; Grahek, Rok; Humar, Vlasta; Husu-Kovacevic, Breda; Jerala-Strukelj, Zdenka
PATENT ASSIGNEE(S): Lek Pharmaceuticals D.D., Slovenia
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005084670	A1	20050915	WO 2005-EP2108	20050228

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: SI 2004-67 A 20040301

AB Compns. were developed which stabilize an active pharmaceutical ingredient in polymorph form susceptible to degradation or interconversion into other polymorph forms, where stabilizing substance is conveniently among silicon dioxide, silicified microcryst. cellulose, magnesium oxide and polyethylene glycol. The polymorphic form of losartan potassium was stable when formulated with Syloid and PEG 6000.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:967720 CAPLUS

DOCUMENT NUMBER: 144:181122

TITLE: Losartan potassium 3.5-hydrate, a new crystalline form

AUTHOR(S): Hu, Xiu Rong; Wang, Yun Wu; Gu, Jian Ming

CORPORATE SOURCE: Center of Analysis and Measurement, Zhejiang University, Zhejiang, 310028, Peop. Rep. China

SOURCE: Acta Crystallographica, Section E: Structure Reports Online (2005), E61(9), m1686-m1688
CODEN: ACSEBH; ISSN: 1600-5368
URL: http://journals.iucr.org/e/issues/2005/09/00/dn6239/dn6239Isup2.hkl

PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal; (online computer file)

LANGUAGE: English

AB Crystals of the title compound are orthorhombic, space group Pbca, with a 13.1389(3), b 25.6885(5), c 31.1822(7) Å; Z = 8, dc = 1.323; R = 0.054, Rw(F2) = 0.124 for 6573 reflections. The asym. unit is composed of two losartan anions, two K+ cations and seven H2O mols. Some H2O mols. bridge the K ions linking the mols. to form an infinite chain. The two K ions have different environments; one is six-coordinated by three water O atoms and three tetrazole N atoms, whereas the other is five-coordinated by five water O atoms. Extensive H-bonding interactions lead to a three-dimensional structure.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:638868 CAPLUS

DOCUMENT NUMBER: 143:139094

TITLE: An improved process for the synthesis of losartan potassium

INVENTOR(S): Kumar, Ashok; Singh, Rajesh Kumar Keshava Prasad; Panda, Nalinakshya Balaram; Upare, Abhay Atmaram;

Nimbalkar, Manmohan Madhavrao; Soudagar, Satish Rajanikant; Saxena, Ashvini Kumar Nand Kishore
PATENT ASSIGNEE(S): Ipca Laboratories Limited, India
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005066158	A2	20050721	WO 2004-IN169	20040615
WO 2005066158	A3	20050825		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IN 2004-MU14 A 20040106

AB Improved processes using primary, secondary and tertiary alcs. and with safer mode of introduction of the reagent and reaction conditions are described. Further, the process of manufacture of losartan potassium by use of alkali metal salt such as potassium carbonate is disclosed. A process for preparation of the polymorphic Form I of losartan potassium is also disclosed herein.
Losartan potassium was prepared by the reaction of potassium tertiary butoxide with trityl losartan in methanol, yield = 78%.

L9 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:527406 CAPLUS
DOCUMENT NUMBER: 143:65424
TITLE: Process for the preparation of crystalline losartan potassium
INVENTOR(S): Razzetti, Gabriele; Magrone, Domenico; Ercoli, Mauro; Allegrini, Pietro; Castaldi, Graziano
PATENT ASSIGNEE(S): Dipharma S.P.A., Italy
SOURCE: U.S. Pat. Appl. Publ., 4 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005131040	A1	20050616	US 2004-10455	20041214
EP 1544198	A1	20050622	EP 2004-27598	20041119

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU

JP 2005179355	A2	20050707	JP 2004-360875	20041214

PRIORITY APPLN. INFO.: IT 2003-MI2472 A 20031216

AB A process for the preparation of crystalline losartan potassium and crystalline hydrate losartan potassium is disclosed. A suspension of losartan in EtOAc was treated with KHCO3 in water to give losartan potassium crystalline hydrate.

L9 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:284148 CAPLUS
DOCUMENT NUMBER: 142:341839
TITLE: Process for the synthesis of losartan potassium
INVENTOR(S): Kumar, Ashok; Singh, Rajesh Kumar Keshava Prasad; Panda, Nalinakshya Balaram; Upare, Abhay Atmaram; Nimbalkar, Manmohan Madhavrao; Soudagar, Satish Rajanikant; Saxena, Ashvini Kumar Nand Kishore
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 12 pp., Cont.-in-part of U.S. Ser. No. 431,847.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005070586	A1	20050331	US 2004-913121	20040805
US 2004224998	A1	20041111	US 2003-431847	20030507
US 6916935	B2	20050712		
PRIORITY APPLN. INFO.:			US 2003-431847	A2 20030507
			US 2003-468208P	P 20030506

AB Improved processes using primary, secondary and tertiary alcs. and with safer mode of introduction of the reagent and reaction conditions are described. Further, the process of manufacture of losartan potassium by use of alkali metal salt such as potassium carbonate is disclosed. A process for preparation of the polymorphic form I of losartan potassium is also disclosed herein. Potassium tertiary butoxide was reacted with trityl losartan in methanol to obtain losartan potassium form I, yield: 78%.

L9 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:280278 CAPLUS
DOCUMENT NUMBER: 143:163500
TITLE: 4'-(2-Butyl-4-chloro-5-formylimidazol-1-ylmethyl)biphenyl-2-carbonitrile
AUTHOR(S): Yathirajan, Hemmige S.; Nagaraj, Basavegowda; Narasegowda, Rajenahally S.; Nagaraja, Padmarajaiah; Bolte, Michael
CORPORATE SOURCE: Department of Studies in Chemistry, University of Mysore, Manasagangotri, Mysore, 570 006, India
SOURCE: Acta Crystallographica, Section E: Structure Reports Online (2005), E61(4), o1193-o1195
CODEN: ACSEBH; ISSN: 1600-5368
URL: http://journals.iucr.org/e/issues/2005/04/00/dn6209/index.html
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English
AB The title compound, C22H20ClN3O, (I), was used as an intermediate for the

synthesis of the antihypertensive drug losartan. Crystallog. data are given. Bond lengths and angles are unexceptional. The crystal packing is stabilized by one C-H···O and one C-H···N contact. It is noteworthy that (I) is isomorphous with a closely related compound which differs in having a but-2-enyl chain instead of a Bu chain on the imidazole ring.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:964836 CAPLUS
DOCUMENT NUMBER: 141:400944
TITLE: Losartan potassium synthesis
INVENTOR(S): Kumar, Ashok; Singh, Rajeshkumar; Panda, Nalinakshya; Upare, Abhay; Nimbalkar, Manmohan; Soudagar, Satish
PATENT ASSIGNEE(S): Ipca Laboratories, India
SOURCE: U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004224998	A1	20041111	US 2003-431847		20030507
US 6916935	B2	20050712			
US 2005070586	A1	20050331	US 2004-913121		20040805
US 2005043539	A1	20050224	US 2004-938317		20040910
PRIORITY APPLN. INFO.:			US 2003-468208P	P	20030506
			US 2003-431847	A2	20030507
			IN 2004-MU80	A	20040128

AB A process for the preparation of losartan potassium (I) by reacting trityllosartan in a primary alc. with a potassium tertiary alkoxide is disclosed. I was prepared in 81.63% yield by refluxing a solution of potassium tert-butoxide in MeOH with trityllosartan for 8 h.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:930812 CAPLUS
DOCUMENT NUMBER: 142:288051
TITLE: Trityl losartan
AUTHOR(S): Sieron, Leslaw; Nagaraj, B.; Prabhuswamy, B.; Yathirajan, H. S.; Nagaraja, P.; Narasegowda, R. S.; Gaonkar, S. L.
CORPORATE SOURCE: Institute of General and Ecological Chemistry, Technical University of Lodz, Lodz, 90-924, Pol.
SOURCE: Acta Crystallographica, Section C: Crystal Structure Communications (2004), C60(11), o821-o823
CODEN: ACSCEE; ISSN: 0108-2701
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The title compound (systematic name: {2-butyl-4-chloro-1-[2'-(2-trityl-2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-1H-imidazol-5-yl}methanol), C41H37ClN6O, crystallizes in the centrosym. space group P.hivin.1 with two independent mols. in the asym. unit.

Crystallog. data are given. These mols. differ significantly only in the relative orientations of the rings in the biphenylyltetrazole moieties. One of the mols. shows disorder for three C atoms in the Bu group. H bonds link the mols. in an infinite chain along the a axis.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:857589 CAPLUS
DOCUMENT NUMBER: 141:337645
TITLE: A process for the synthesis of losartan potassium
INVENTOR(S): Kumar, Ashok; Singh, Rajesh Kumar; Panda, Nalinakshya; Upare, Abhay Atmaram; Nimbalkar, Manmohan Madhavrao; Soudagar, Satish Rajanikant
PATENT ASSIGNEE(S): Ipca Laboratories Limited, India
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087691	A1	20041014	WO 2003-IN230	20030627
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003269470	A1	20041025	AU 2003-269470	20030627
EP 1608641	A1	20051228	EP 2003-751250	20030627
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: IN 2003-MU335 A 20030403
WO 2003-IN230 W 20030627

AB A process for the synthesis of losartan potassium comprises reacting trityl losartan in a primary alc. with potassium tertiary alkoxide. A solution of potassium tertiary butoxide in methanol was refluxed with trityl losartan under N for 8 h to obtain losartan potassium which was separated and purified (yield=81.63%).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:740318 CAPLUS
DOCUMENT NUMBER: 141:248755
TITLE: Amorphous form of losartan potassium
INVENTOR(S): Parthasaradhi, Reddy Bandi; Rathnakar, Reddy Kura; Raji, Reddy Rapolu; Narasa, Reddy Attunuri; Narasa, Reddy Bolla
PATENT ASSIGNEE(S): Hetero Drugs Limited, India
SOURCE: PCT Int. Appl., 8 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076443	A1	20040910	WO 2003-IN37	20030225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003209669	A1	20040917	AU 2003-209669	20030225
PRIORITY APPLN. INFO.:			WO 2003-IN37 A	20030225

AB The invention relates to a novel amorphous form of losartan potassium, to a process for the preparation thereof, and to a composition containing it. Losartan potassium crystals (50 g) were added to a mixture containing MeOH and EtOAc and the solution was dried for 18 h to give 42 g losartan potassium.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:740317 CAPLUS
DOCUMENT NUMBER: 141:265973
TITLE: Preparation of polymorphic crystal forms of the antihypertensive agent losartan potassium
INVENTOR(S): Kumar, Pananchukunnath Manoj; Manikandan, Ramalingam; Singh, Romi Barat; Nagaprasad, Vishnubhotla; Malik, Rajiv
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076442	A1	20040910	WO 2004-IB516	20040227
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,				

GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: IN 2003-DE202 A 20030228
AB Processes for producing polymorphic crystal forms of losartan potassium (I), useful as an antihypertensive, are claimed as are the crystal polymorphs of I, their crystal-characterization data, and their use in pharmaceutical formulations.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:740288 CAPLUS
DOCUMENT NUMBER: 141:248753
TITLE: Preparation of losartan potassium polymorphs
INVENTOR(S): Boccignone, Andrea; Malpezzi, Luciana; Castaldi, Graziano; Allegrini, Pietro; Beltrame, Andrea
PATENT ASSIGNEE(S): Dinamite Dipharma S.P.A. In Abbreviate Form Dipharma S.P.A., Italy; Dipharma S.P.A.
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076406	A2	20040910	WO 2004-EP1717	20040220
WO 2004076406	A3	20050113		

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IT 2003-MI328 A 20030225
AB Losartan potassium polymorphs, identified as losartan potassium crystalline hydrate, losartan potassium amorphous and losartan potassium modification crystalline III, a process for their preparation, pharmaceutical compns. containing them and their use in therapy. Thus, losartan was dissolved in MeOh and treated with KHCO3 to give a losartan potassium polymorph III.

L9 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:648382 CAPLUS
DOCUMENT NUMBER: 141:179636
TITLE: Purification methods in preparation of pharmaceutical salts of losartan
INVENTOR(S): Antoncic, Ljubomir; Copar, Anton; Svete, Peter; Husu-Kovacecic, Breda; Ham, Zoran; Marolt, Boris
PATENT ASSIGNEE(S): Lek Pharmaceuticals D.D., Slovenia

SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004066997	A2	20040812	WO 2004-SI1	20040129
WO 2004066997	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
SI 21423	C	20040831	SI 2003-25	20030130
SI 21424	C	20040831	SI 2003-26	20030130
SI 21508	C	20041231	SI 2003-145	20030612
SI 21509	C	20041231	SI 2003-157	20030626
EP 1589966	A2	20051102	EP 2004-706411	20040129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006004207	A1	20060105	US 2005-524993	20050218

PRIORITY APPLN. INFO.:

SI 2003-25	A	20030130
SI 2003-26	A	20030130
SI 2003-145	A	20030612
SI 2003-157	A	20030626
SI 2003-270	A	20031105
WO 2004-SI1	W	20040129

AB Pharmaceutical crystalline and amorphous alkali and alkaline earth salts of losartan are prepared and new manufacturing, purification and isolation procedures for the salts in high purity are disclosed. Stable pharmaceutical compns. containing new crystalline potassium salts of losartan were prepared Thus, losartan potassium was prepared from losartan by treatment with KOH in iso-PrOH. Film-coated tablets contained losartan potassium 100.000 mg.

L9 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:589438 CAPLUS
DOCUMENT NUMBER: 141:111635
TITLE: Body weight gain inhibitors containing angiotensin II antagonists
INVENTOR(S): Terashita, Zen-ichi; Kusumoto, Keiji; Yamaguchi, Fuminari; Imura, Yoshimi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060399	A1	20040722	WO 2003-JP16656	20031225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,				

OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2511737	AA	20040722	CA 2003-2511737	20031225
AU 2003292775	A1	20040729	AU 2003-292775	20031225
JP 2004217648	A2	20040805	JP 2003-429424	20031225
EP 1579872	A1	20050928	EP 2003-768195	20031225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1756567	A	20060405	CN 2003-80110043	20031225
US 2006069133	A1	20060330	US 2005-540369	20050623
PRIORITY APPLN. INFO.:			JP 2002-380386 A	20021227
			WO 2003-JP16656 W	20031225

OTHER SOURCE(S): MARPAT 141:111635

AB It is intended to provide a drug showing an excellent effect of inhibiting body weight gain which contains a compound having an angiotensin II antagonism, its prodrug or a slat thereof. It is also intended to provide a drug capable of inhibiting body weight gain in a patient even in the case of administering a therapeutically efficacious PPARγ-agonistic substance in treating diabetes or other diseases. The effect of 2-ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]benzimidazol-7-carboxylic acid (I) on PPARγ-agonistic substance (pioglitazone)-induced obesity in rats was examined A capsule containing I 5, pioglitazone hydrochloride 30, lactose 85, fine cryst . cellulose 70, magnesium stearate 10 mg was formulated.

L9 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:414643 CAPLUS
DOCUMENT NUMBER: 140:412339
TITLE: Crystalline form of losartan potassium
INVENTOR(S): Reddy, Manne Satyanarayana; Eswaraiah, Sajja; Koppera, Ravinder Reddy; Reddy, Vajrala Venkata
PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004097568	A1	20040520	US 2003-629316	20030729
PRIORITY APPLN. INFO.:			IN 2002-MA568 A	20020729

AB A compound that is a crystalline Form III of losartan potassium is provided. Also provided are compns. containing the compound and methods for its preparation For example, 125 g of trityl losartan (preparation given) was mixed with an aqueous solution containing 11 g of KOH, 125 mL water, and 1250 mL methanol until the reaction was complete. The solvent was distilled off the reaction solution under vacuum, and water (325 mL) added to the residual mass, stirred for 30 min, the pH adjusted to 8.2 to 8.8, and the mass filtered. The filtrate was washed with water, the water was distilled off, and the resulting residue was dissolved in methanol,

the solvent distilled off, and the residual mass cooled to a temperature of 5 to 10°, filtered, and dried to yield crystalline polymorph Form III of losartan potassium (weight 43.0 g). The crystalline polymorph Form III of losartan potassium was also obtained from cryst . polymorph Form I of losartan potassium.

L9 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:454301 CAPLUS
DOCUMENT NUMBER: 139:26612
TITLE: Amorphous and crystalline forms of losartan potassium
INVENTOR(S): Dolitzky, Ben Zion; Weizel, Shlomit; Nisnevich, Gennady; Rukhman, Igor; Kaftanov, Julia
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries, Ltd., Israel; Teva Pharmaceuticals USA, Inc.
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003048135	A1	20030612	WO 2002-US36550		20021113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2465597	AA	20030612	CA 2002-2465597		20021113
AU 2002360386	A1	20030617	AU 2002-360386		20021113
US 2004006237	A1	20040108	US 2002-293820		20021113
EP 1458693	A1	20040922	EP 2002-795637		20021113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
CN 1612866	A	20050504	CN 2002-826988		20021113
JP 2006504618	T2	20060209	JP 2003-549327		20021113
ZA 2004003582	A	20050511	ZA 2004-3582		20040511
NO 2004002434	A	20040611	NO 2004-2434		20040611
PRIORITY APPLN. INFO.:			US 2001-333034P	P	20011114
			US 2002-401278P	P	20020805
			WO 2002-US36550	W	20021113

AB This invention relates to novel amorphous losartan potassium, novel losartan potassium in a crystalline form that is a hydrate, novel crystalline losartan potassium Form IV and solvates thereof, novel crystalline losartan potassium Form V and solvates thereof, to processes for their preparation, to compns. containing them and to their use in medicine. This invention further relates to a novel process for preparing crystalline losartan potassium Form I and Form II.
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:906207 CAPLUS
DOCUMENT NUMBER: 138:4604
TITLE: Deprotection process for the crystallization of losartan potassium in the polymorphic crystalline form I
INVENTOR(S): Ramashankar; Reddy, Ravinder Vennapu; Sivakumaran, Meenakshisunderam; Handa, Vijay Kumar
PATENT ASSIGNEE(S): Aurobindo Pharma Limited, India
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094816	A1	20021128	WO 2001-IN205	20011120
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 193625	A	20040731	IN 2001-MA403	20010518
EP 1294712	A1	20030326	EP 2001-274254	20011120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
SI 21236	C	20031231	SI 2001-20042	20011120
JP 2004520446	T2	20040708	JP 2002-591489	20011120
BG 107478	A	20040130	BG 2003-107478	20030117

PRIORITY APPLN. INFO.:
IN 2001-MA403 A 20010518
IN 2001-CH403 A 20010518
WO 2001-IN205 W 20011120

OTHER SOURCE(S): CASREACT 138:4604; MARPAT 138:4604
GI



I

AB The polymorphic crystalline form I of losartan

potassium (I; R = K) is prepared in high yield and selectivity by the deprotection of a losartan precursor (I; R = H, CPh3; e.g., trityl lorsartan) with potassium hydroxide in an alc. (e.g., methanol), followed by reducing the alc. concentration under vacuum, and adding a nonsolvent (e.g., acetone) to precipitate the losartan potassium.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:496878 CAPLUS
DOCUMENT NUMBER: 137:286738
TITLE: Losartan potassium, a non-peptide agent for the treatment of arterial hypertension
AUTHOR(S): Fernandez, Daniel; Vega, Daniel; Ellena, Javier A.; Echeverria, Gustavo
CORPORATE SOURCE: Escuela de Ciencia y Tecnologia, Universidad Nacional de General San Martin, Buenos Aires, Argent.
SOURCE: Acta Crystallographica, Section C: Crystal Structure Communications (2002), C58(7), m418-m420
CODEN: ACSCEE; ISSN: 0108-2701
PUBLISHER: Blackwell Munksgaard
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Crystals of the title compound, potassium 2-butyl-4-chloro-1-{[2'-(5-tetrazolido)biphenyl-4-yl]methyl}-1H-imidazol-5-ylmethanol, are monoclinic, space group P21/c, with a 15.5724(3), b 7.4976(2), c 24.2640(5) Å,, β 128.4980(10)°; Z = 4, dc = 1.381; R = 0.043, Rw(F2) = 0.116 for 3888 reflections. The imidazole and tetrazole rings are at angles of 85.0(2) and 51.8(1)°, resp., to the Ph rings to which they are attached, while the dihedral angle between the latter two rings is 46.7(1)°. The coordination sphere of the metal cation consists of six tetrazolyl N atoms, the MeOH O atom and the π cloud of one of the Ph rings. These interactions determine the formation of columns of mol. anions that lie parallel to the b axis, while H bonding contributes to intercolumnar cohesion. Far from the center of the columns, the hydrocarbon chain is immersed in a hydrophobic environment.
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:207516 CAPLUS
DOCUMENT NUMBER: 136:236883
TITLE: Blood pressure-lowering compositions containing caffeic acid derivatives
INVENTOR(S): Suzuki, Atsushi; Ochiai, Ryuji; Kagawa, Taiji; Tokimitsu, Ichiro
PATENT ASSIGNEE(S): Kao Corp., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002080354	A2	20020319	JP 2000-268099	20000905
PRIORITY APPLN. INFO.:			JP 2000-268099	20000905

AB This invention relates to blood pressure-lowering compns. containing (1) caffeic acid, chlorogenic acid, ferulic acid, and/or esters and salts thereof and (2) antihypertensives. For example, soft capsules were formulated containing caffeic acid 5, enalapril 5, corn starch 44, crystalline cellulose 40, CaCMC 5, silica 0.5, and Mg stearate 0.5 %.

L9 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:798216 CAPLUS
DOCUMENT NUMBER: 135:344489
TITLE: Detritylation process for the synthesis of losartan potassium using potassium hydroxide and a C1-4 alkanol solvent
INVENTOR(S): Fischer, Janos; Ballo, Ildiko; Petenyi, Endrene; Kreidl, Janos; Czibula, Laszlo; Nemes, Andras; Deutsch Juhasz, Ida; Werk Papp, Eva; Nagy Bagdy, Judit; Hegedus, Istvan; Farkas, Jenome
PATENT ASSIGNEE(S): Richter Gedeon Vegyeszeti Gyar Rt., Hung.
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081336	A1	20011101	WO 2001-HU47	20010420
WO 2001081336	C1	20020829		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001054998	A5	20011107	AU 2001-54998	20010420
EP 1274702	A1	20030115	EP 2001-928134	20010420
EP 1274702	B1	20040211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531203	T2	20031021	JP 2001-578426	20010420
EE 200200460	A	20031215	EE 2002-460	20010420
AT 259366	E	20040215	AT 2001-928134	20010420
ES 2215130	T3	20041001	ES 2001-1928134	20010420
US 2003078435	A1	20030424	US 2002-182109	20020724
US 6710183	B2	20040323		
BG 107031	A	20030829	BG 2002-107031	20020823
PRIORITY APPLN. INFO.:			HU 2000-1618 A	20000421
			WO 2001-HU47 W	20010420

OTHER SOURCE(S): CASREACT 135:344489; MARPAT 135:344489
AB Losartan potassium (m.p. 262-264°) is prepared in high yield and selectivity by reacting the corresponding tritylated derivative [e.g., 2-butyl-4-chloro-1-[[2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl]-1H-imidazole-4-methanol] in an C1-4 alkanol (e.g., methanol) solvent with 0.1-1 equiv of potassium hydroxide and isolating the product after crystallizing out by changing the solvent to an aprotic (e.g., acetonitrile) or weakly protic solvent.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:338762 CAPLUS
DOCUMENT NUMBER: 134:362292
TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile
INVENTOR(S): Farr, Spencer
PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA
SOURCE: PCT Int. Appl., 222 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-165398P P 19991105
US 2000-196571P P 20000411

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to determine the hypersensitivity of individuals to a given agent, such as drug or other chemical, in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes associated with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes associated with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes associated with hypersensitivity. The expression of the genes predetd. to be associated with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and apparatus useful for identifying hypersensitivity in a subject are also disclosed.

L9 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:45216 CAPLUS
DOCUMENT NUMBER: 130:115010
TITLE: Process for the crystallization of losartan
INVENTOR(S): Breen, Patrick; Dienemann, Erik A.; Epstein, Albert D.; Larson, Karen A.; Kennedy, Michael T.; Mahadevan, Hari
PATENT ASSIGNEE(S): Merck and Co., Inc., USA

SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5859258	A	19990112	US 1997-959209	19971028
PRIORITY APPLN. INFO.:			US 1997-959209	19971028

AB Losartan potassium (I) is an angiotensin II antagonist useful in the treatment of hypertension and congestive heart failure. This invention relates to the process for the controlled crystallization of losartan potassium utilizing anti-solvent addition combined with massive seeding in order to obtain the desired crystal morphol. and bulk phys. properties necessary for successful formulation. Isopropanol 25.4 kg and 8.0 kg I were charged to a vessel along with 930 mL of distilled water. In a sep. vessel, 12.4 kg cyclohexane and 40 g I milled seed were heated to 60-65° and added to the above vessel until the solution became cloudy. The KF (Karl Fischer titration) at which the cloud point occurred was 1.90 % and the amount of cyclohexane slurry used to reach the cloud point was 6.2 kg. The batch was then seeded with 400 g finely-milled I and aged at reflux (70°) for 1 h. The batch was distilled at constant volume with simultaneous addition of 35 kg of 75:25 cyclohexane:isopropanol to achieve a batch KF of 0.54%. Distillates were collected with addition of 6 kg of cyclohexane to the batch during the concentration step. The batch was filtered under a N atmospheric and the cake was washed with 20 kg of 75:25 cyclohexane:isopropanol followed by 20 kg of cyclohexane. The batch was dried on trays at 45-50° under vacuum to obtain highly purified crystals of I.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:293497 CAPLUS
DOCUMENT NUMBER: 128:326548
TITLE: Process for the crystallization of losartan
INVENTOR(S): Breen, Patrick; Dienemann, Erik A.; Epstein, Albert D.; Larson, Karen A.; Kennedy, Michael T.; Mahadevan, Hari
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Breen, Patrick; Dienemann, Erik A.; Epstein, Albert D.; Larson, Karen A.; Kennedy, Michael T.; Mahadevan, Hari
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9818787	A1	19980507	WO 1997-US19442	19971024

W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US,

UZ, VN, YU
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9850898	A1	19980522	AU 1998-50898		19971024
EP 937068	A1	19990825	EP 1997-913800		19971024
EP 937068	B1	20020313			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI, RO					
BR 9712390	A	19990831	BR 1997-12390		19971024
CN 1241186	A	20000112	CN 1997-180909		19971024
CN 1101393	B	20030212			
JP 2000504343	T2	20000411	JP 1998-520675		19971024
JP 3249827	B2	20020121			
AT 214388	E	20020315	AT 1997-913800		19971024
PT 937068	T	20020731	PT 1997-913800		19971024
ES 2173433	T3	20021016	ES 1997-913800		19971024
SK 282875	B6	20030109	SK 1999-570		19971024
HR 970565	B1	20030228	HR 1997-970565		19971024
CZ 291672	B6	20030416	CZ 1999-1515		19971024
TW 411338	B	20001111	TW 1997-86116083		19971029
PRIORITY APPLN. INFO.:			US 1996-29326P	P	19961029
			GB 1996-25804	A	19961212
			US 1996-29326	P	19961029
			WO 1997-US19442	W	19971024

AB Losartan potassium is an angiotensin II antagonist useful in the treatment of hypertension and congestive heart failure. This invention relates to the process for the controlled crystallization of losartan potassium utilizing anti-solvent addition combined with massive seeding in order to obtain the desired crystal morphol. and bulk phys. properties necessary for successful formulation.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:890142 CAPLUS
DOCUMENT NUMBER: 123:313978
TITLE: Polymorphs of losartan potassium and a process for the preparation of polymorph forms I and II of losartan potassium
INVENTOR(S): Campbell, Gordon Creston, Jr.; Dwivedi, Anil M.; Levorse, Dorothy A.; McCauley, James A.; Raghavan, Krishnaswamy S.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA; du Pont de Nemours, E. I., and Co.; Dupont Merck Pharmaceutical Co.
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9517396	A1	19950629	WO 1994-US14768	19941221
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ				

RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
CA 2179067	AA	19950629	CA 1994-2179067		19941221
AU 9514058	A1	19950710	AU 1995-14058		19941221
AU 685898	B2	19980129			
EP 736021	A1	19961009	EP 1995-905449		19941221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
JP 09507075	T2	19970715	JP 1994-517594		19941221
US 5608075	A	19970304	US 1995-371937		19950112
PRIORITY APPLN. INFO.:			US 1993-173440	A	19931223
			WO 1994-US14768	W	19941221

GI



I

AB Polymorphic forms of losartan potassium, I, a known angiotensin II-inhibiting antihypertensive, are prepared Numerous spectral, thermal, and X-ray data of I form I and II are reported, and I-containing formulations are presented along with angiotensin II receptor inhibition data.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	88.44	255.59

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION

Andrew Freistein 10/524,993

CA SUBSCRIBER PRICE -20.25 -20.25

STN INTERNATIONAL LOGOFF AT 11:23:49 ON 16 AUG 2006